Data Requirements for Patenting Biotech/Pharma Inventions in China and the EU

In Webinars

1 July, 2020

This interactive webinar considers the filing and post-filing data requirements for biotechnology and pharmaceutical-related inventions in China and the EU. Xiaofan Chen, Hai Liu and Helle Friis Svenstrup from AWA’s Asian and European offices explain the minimum data requirements during filing and also the criteria for supplementary data. They also consider the use of post-grant data as evidence during invalidation proceedings. Understanding the differences between the European and Chinese regimes is essential for applicants to be successful.

 

 

 

You may also be interested in:

The Business of IP – Understanding and Creating Value: Part 4 – Spin Offs

In this six-part series, Anders Isaksson explores some of the critical factors and motivators for why companies, small or

Read more...

Was this the last hurdle for German UPCA Ratification?

At the end of 2020, German ratification of the Agreement on a Unified Patent Court (UPCA) looked promising as

Read more...

Attracting Capital – Guiding the Growth Journey

In a series of programs initiated by AWA Denmark, the focus will be on what potential growth entrepreneurs should

Read more...

Mobile Sliding Menu